Alteration of Prognostic Factors for Patients with Brain Metastases from Lung Cancer Before and After the Introduction of Immune Checkpoint Inhibitors: A Retrospective Single-Institution Study
ICIs significantly improved survival in patients with lung cancer brain metastases, particularly those with squamous cell carcinoma or small cell carcinoma. NLR may provide supportive prognostic information, while molecular targeted therapy and ICIs represent major drivers of improved survival in this population.
Authors
- Naoki Kato (ORCID: https://orcid.org/0000-0001-5041-6985)
- Yasuki Yamamoto (ORCID: https://orcid.org/0009-0008-1930-481X)
- Yuichi Murayama (ORCID: https://orcid.org/0000-0003-3490-385X)
- Tomoki Maetani (ORCID: https://orcid.org/0000-0001-5063-662X)
- Toshihide Tanaka (ORCID: https://orcid.org/0000-0002-6474-6317)
- Yasuo Terasawa (ORCID: https://orcid.org/0000-0002-4535-8589)
- Yasuharu Akasaki (ORCID: https://orcid.org/0000-0001-8015-084X)
- H Narita
Institutions
- Jikei University School of Medicine (JP)
- The Jikei University Hospital (JP)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3390/cancers17183067
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00